Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of various cancers. The company operates in the biotechnology industry, specifically within immuno-oncology, and has developed two proprietary platform technologies, ADAPTIR™ and ADAPTIR-FLEX™, for the rational design of precision immune modulatory drugs. The company has two clinical candidates and six preclinical candidates in development, all derived from these platforms. The company's strategy emphasizes advancing its lead clinical candidates, expanding its multi-specific antibody pipeline, and establishing collaborative partnerships to broaden its pipeline and secure funding for research and development. The company believes its candidates will be highly competitive due to their design for safety, tolerability, and efficacy, noting that 11 bispecifics have been approved as cancer treatments to date by the FDA, with over 100 more in clinical development ¹.

The core business model revolves around the discovery, development, and potential commercialization of novel immunotherapy candidates for cancer treatment. Revenue generation is currently primarily through financing activities and potential milestone payments from collaborations, rather than product sales, as the company has no commercially approved products ². Primary customer segments, if products reach commercialization, would be healthcare providers and patients in oncology. The company's proprietary ADAPTIR and ADAPTIR-FLEX platforms are central to its strategy, enabling the efficient design and creation of new molecules and supporting long-term growth by generating monospecific and multi-specific antibody candidates that enhance the human immune system against cancer cells ³.

The company's product pipeline includes two clinical candidates and six preclinical candidates. Mipletamig is a bispecific ADAPTIR designed to engage CD3 and CD123 to redirect T cells to destroy leukemia cells expressing CD123. It has received Orphan Drug Designation from the FDA for acute myeloid leukemia (AML) ⁴. Mipletamig is currently being evaluated in the RAINIER trial, a Phase 1b/2 dose optimization study initiated in August 2024, for frontline AML patients in combination with venetoclax + azacitidine ⁵. Previous monotherapy trials showed clinical benefit in 49% of evaluable AML patients in Phase 1a, with two complete remissions observed ⁶. In combination therapy, mipletamig demonstrated an 82% composite clinical remission rate and 73% complete remission/complete remission with incomplete hematologic recovery (CR/CRi) in Cohort 2 of the Phase 1b dose expansion trial in venetoclax naive patients ⁷. Notably, 100% of evaluable frontline patients in the RAINIER trial and completed dose expansion trial (N=28) have remained free of cytokine release syndrome (CRS), with an 86% clinical benefit rate and 79% achieving CR or CRi ⁸.

ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate, developed in partnership with Alligator Bioscience AB, targeting 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen) for the treatment of multiple solid tumor types ⁹. The completed Phase 1 dose escalation trial showed no severe liver toxicity and 59% of efficacy-evaluable patients (10 of 17) achieved stable disease, with 4 patients having long-term stable disease of over 10 cycles (5 months) ¹⁰. Preclinical candidates include APVO603, a dual agonist bispecific ADAPTIR targeting 4-1BB and OX40 for multiple solid tumors; APVO442, a novel bispecific ADAPTIR-FLEX candidate targeting PSMA on prostate cancer cells; APVO711, a bispecific checkpoint inhibitor targeting PD-L1 and CD40 for multiple solid tumor types; APVO455, a Nectin-4 x CD3 bispecific T cell engager for tumors like bladder, breast, NSCLC, and head and neck cancers; APVO451, a trispecific ADAPTIR-FLEX targeting nectin-4, CD40, and CD3 for a broad range of solid tumors; and APVO452, a trispecific ADAPTIR-FLEX targeting PSMA, CD40, and CD3 for prostate cancers ¹¹.

For the fiscal year ended December 31, 2025, the company reported a net loss of $26.0 million ¹², compared to a net loss of $24.1 million for the same period in 2024 ¹³. Research and development expenses increased slightly to $14.5 million in 2025 from $14.4 million in 2024, primarily due to increased mipletamig and employee costs, offset by lower costs for ALG.APV-527 as its dose escalation trial concluded ¹⁴. General and administrative expenses rose by $1.6 million, from $10.2 million in 2024 to $11.8 million in 2025, mainly due to higher employee, consulting, and legal costs ¹⁵. Other income, net, decreased from $0.5 million in 2024 to $0.3 million in 2025, primarily due to lower interest and rental income ¹⁶. As of December 31, 2025, cash and cash equivalents stood at $21.6 million ¹⁷, with an accumulated deficit of $275.1 million ¹⁸. Net cash used in operating activities was $25.6 million in 2025 ¹⁹, compared to $23.8 million in 2024 ²⁰. Net cash provided by financing activities was $38.5 million in 2025, primarily from $37.9 million in net proceeds from common stock issuance and $0.6 million from common warrant exercises ²¹.

Year-over-year, the net loss increased from $24.1 million in 2024 to $26.0 million in 2025 ²². Research and development expenses saw a modest increase of $0.1 million, driven by higher mipletamig and employee costs, while ALG.APV-527 costs decreased ²³. General and administrative expenses increased by $1.6 million ²⁴. The company's cash and cash equivalents significantly increased from $8.7 million in 2024 to $21.6 million in 2025 ²⁵, largely due to financing activities. The company also reported a dividend attributable to a down-round feature of warrants of $1.571 million in 2025, which was not present in 2024 ²⁶.

Significant operational developments during the period include the initiation of the RAINIER Phase 1b/2 trial for mipletamig in August 2024 ²⁷, which has shown promising initial results with 100% of frontline patients remaining free of cytokine release syndrome ²⁸. The company also expanded its CD3 portfolio with three new multispecific candidates, including its first two trispecific assets, leveraging its proprietary CRIS7-derived CD3 binding domain ²⁹. This expansion aims to address a wider range of tumor targets and combination strategies in immune-oncology ³⁰. The company also strengthened its financial capacity by establishing a $60 million equity line facility in 2026, providing additional access to capital ³¹.

Management explicitly states that the company will require additional funding to support its operating and capital needs, beyond its existing cash resources, future IXINITY milestone payments, and proceeds from equity offerings and warrant exercises ³². The company anticipates continuing to incur significant operating losses for the next several years as it executes its development strategy for preclinical and clinical-stage assets ³³. The company's future success is dependent on its ability to develop product candidates and raise capital on acceptable terms ³⁴.

A major growth area is the advancement of mipletamig through clinical development. The RAINIER trial, a Phase 1b/2 dose optimization study, is underway for frontline AML patients, with expected conclusion in the second half of 2026 ³⁵. Positive initial results from this trial, showing 100% of frontline patients free of cytokine release syndrome and an 86% clinical benefit rate, underscore mipletamig's safety and combinability, potentially offering a superior treatment ³⁶. The company believes this data supports continued development for frontline patients unfit for high-intensity chemotherapy ³⁷.

Another key growth area is the advancement of ALG.APV-527, developed in partnership with Alligator Bioscience AB, for multiple solid tumor types ³⁸. The completed Phase 1 dose escalation trial demonstrated positive safety and tolerability, with no severe liver toxicity, and clinical activity, with 59% of efficacy-evaluable patients achieving stable disease ³⁹. Aptevo and Alligator are currently evaluating next steps for the dose expansion trial ⁴⁰.

The company also plans to advance its multi-specific antibody pipeline, with a particular emphasis on its CD3-based portfolio, leveraging the differentiated safety profile demonstrated by mipletamig ⁴¹. This includes progressing programs directed at well-validated tumor antigens and immune pathways such as PSMA, Nectin-4, CD40, PD-L1, 4-1BB, and OX40, through preclinical and IND-enabling activities ⁴². The company aims to generate additional monospecific, bispecific, and multi-specific protein immunotherapies, potentially with other collaborative partners, to expand the ADAPTIR and ADAPTIR-FLEX product pipelines and address unmet medical needs ⁴³.

Regarding operational outlook, the company expects its research and development spending to be dependent on factors such as clinical trial results, reimbursement availability, the number of product candidates, and the size and duration of clinical programs ⁴⁴. The company also highlights that it does not have manufacturing capabilities and relies on a limited number of third-party suppliers for product candidate production ⁴⁵. Any performance failure or capacity issues from these manufacturers could delay clinical development or marketing approval ⁴⁶.

For planned capital allocation, the company has established a $60.0 million equity line facility (Second SEPA) with Yorkville in January 2026, which, if fully utilized, is expected to support operations into 2029 ⁴⁷. As of December 31, 2025, the company had $8.7 million remaining availability under the First SEPA ⁴⁸, and subsequently sold 0.09 million shares under the First SEPA for $0.6 million net proceeds and 0.1 million shares under the Second SEPA for $0.6 million net proceeds ⁴⁹. The company also has 676,968 common warrants outstanding, which could provide up to an additional $19.8 million in gross proceeds if exercised ⁵⁰. The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future, intending to retain all available funds for business operations ⁵¹.

Management explicitly flagged several structural headwinds and execution risks. The company has a history of losses and may not be profitable in the future, with a net loss of $26.0 million in 2025 and an accumulated deficit of $275.1 million ⁵². Management and the board have concluded that substantial doubt exists about the company's ability to continue as a going concern ⁵³. The company will require additional capital and may be unable to raise it when needed or on acceptable terms, with current capital market conditions, including inflation and fluctuating interest rates, increasing the cost of capital ⁵⁴. Delays or difficulties in clinical trials, including patient enrollment, could delay regulatory approvals ⁵⁵. Serious adverse events or undesirable side effects of product candidates could delay or prevent regulatory approval or limit commercial potential ⁵⁶. The company's reliance on third parties for clinical trials and manufacturing poses risks if these parties do not perform effectively or meet deadlines ⁵⁷.

Geographic, regulatory, and macro factors identified as constraints include macroeconomic conditions such as rising and fluctuating inflation, market volatility, bank failures, economic uncertainty, supply chain constraints, and political events like potential U.S. federal government shutdowns and evolving healthcare policies ⁵⁸. These factors could adversely affect the business, increase labor and operating costs, and impact the ability to raise capital ⁵⁹. Changes in healthcare reform measures could also negatively affect the business by limiting reimbursement amounts or imposing additional regulatory requirements ⁶⁰. The company's ability to use net operating losses to offset future taxable income may be limited by Section 382 of the U.S. Internal Revenue Code due to potential ownership changes, including one identified in June 2025, which could permanently limit the use of approximately $0.8 million in tax credits ⁶¹.

The company faces material financial risks, including a history of significant operating losses, with a net loss of $26.0 million in 2025 and an accumulated deficit of $275.1 million as of December 31, 2025 ⁶². Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for the one-year period from the financial statement issuance date ⁶³. The company's ability to raise additional capital is crucial, with only $21.6 million in cash and cash equivalents as of December 31, 2025 ⁶⁴, and future financing availability is uncertain and subject to macroeconomic conditions, including fluctuating interest rates, economic uncertainty, and capital market volatility ⁶⁵. Operational risks include potential delays or difficulties in clinical trials, such as patient enrollment, which could delay regulatory approvals and increase development costs ⁶⁶. The company is heavily reliant on third parties for conducting clinical trials and manufacturing, and any failure by these third parties could substantially harm the business ⁶⁷. Product development risks include the possibility that preclinical and clinical trial results may not satisfy regulatory requirements, and interim data may not be predictive of final results ⁶⁸. Serious adverse events or undesirable side effects of product candidates could lead to regulatory delays, withdrawal of approval, or limited commercial potential ⁶⁹. Intellectual property risks include the potential inability to obtain or maintain patent protection, challenges to existing patents, and the risk of infringing on third-party intellectual property rights, which could lead to substantial litigation costs and diversion of management attention ⁷⁰. Regulatory risks include ongoing obligations and review by the FDA and other authorities, with potential penalties for non-compliance, and the impact of evolving healthcare laws and policies that could limit marketability or impose additional burdens ⁷¹. Geopolitical and macroeconomic factors, such as rising inflation, supply chain constraints, and political events, could adversely affect business operations and financial condition ⁷². The company's common stock is subject to volatility, and there is a risk of delisting from the Nasdaq Capital Market if compliance with listing requirements, such as the $1.00 minimum bid price, is not maintained ⁷³.

Management's message to shareholders conveys a focus on advancing its clinical pipeline and expanding its proprietary platform technologies, while acknowledging significant financial challenges. The company emphasizes the promising clinical performance of mipletamig, particularly in combination therapy for frontline AML patients, highlighting its differentiated safety profile with no cytokine release syndrome observed in frontline patients and an 86% clinical benefit rate ⁷⁴. Management also stresses the expansion of its CD3 portfolio with new multispecific candidates, leveraging its ADAPTIR and ADAPTIR-FLEX platforms to address a wider range of tumor targets ⁷⁵. A key strategic priority is strengthening financial capacity, as evidenced by the establishment of a $60.0 million equity line facility in January 2026, which, if fully utilized, is expected to support operations into 2029 ⁷⁶. However, management explicitly states that substantial doubt exists about the company's ability to continue as a going concern, necessitating additional funding beyond current resources and potential milestone payments ⁷⁷. The company also highlights the upcoming leadership transition, with Marvin L. White moving to Executive Chair and Jeffrey G. Lamothe assuming the role of President and Chief Executive Officer, effective April 1, 2026 ⁷⁸.